Novo Nordisk to Pay $2 Billion for New Weight Loss Drug
TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24. The drug, called UBT251, is being developed by United Bio-Technology (Hengqin) Co., a Chinese pharmaceutical company.
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent underwhelming data for CagriSema, but the Danish pharma has given itself another | The candidate at the center of the deal,
President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC ...
Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...
2don MSN
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the ...
The business-software group claimed the top spot as Europe’s largest company by market value, dethroning Wegovy maker Novo ...
Danish company Novo Nordisk's membership in a UK pharmaceutical industry body has been restored after a two-year suspension ...
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback